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ABSTRACT
Objective: The study’s purpose has been to relate the drug interactions of oral anticoagulants with other 
medications used by elderly people hospitalized in a cardiology hospital. Methods: It is a prospective 
exploratory study with 16 elderly people taking oral anticoagulant, who were hospitalized at a governmental 
cardiology institution in São Paulo State over the period from November to December 2017. Results: Among 
73 medicines prescribed and analyzed in the Micromedex 2.0, 24 (33.3%) interacted with Warfarin, the only 
prescribed oral anticoagulant. There were found Omeprazole (70; 97.2%); Dipyrone (68; 94.4%); Simvastatin 
(43; 59.72%); Enoxaparin (42; 58.33%); Amiodarone (29; 40.27%); Sertraline (28; 38.88%); Spironolactone (21; 
29.16%); and Atenolol (11; 15.27%), whose interactions could either potentialize or inhibit the anticoagulant 
action. Considering the interactions, 14 (58.33%) were of moderate severity, 10 (41.66%) of high severity and 
14 (58.33%) of fast effect. Conclusion: Polypharmacy and the use of oral anticoagulants in elderly patients 
bearing heart diseases are common events. Moreover, a better understanding about drug interactions is also 
required, bearing in mind that they can either potentialize or decrease the anticoagulant effect, with high or 
moderate severity. 
Descriptors: Anticoagulation, Elderly People, Hospitalization, Drug Interactions.
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RESUMO
Objetivo: Relacionar as interações medicamentosas dos anticoagulantes 
orais com os medicamentos utilizados por idosos internados em hospital 
cardiológico. Método: Estudo exploratório, prospectivo, com 16 idosos 
em uso de anticoagulantes orais, internados numa instituição cardiológica 
governamental de São Paulo entre novembro e dezembro de 2017. Resultados: 
Dentre 73 medicamentos prescritos e analisados no Micromedex 2.0, 24 
(33,3%) interagiam com a Varfarina, único anticoagulante oral prescrito. 
Encontrou-se Omeprazol (70;97,2%); Dipirona (68;94,4%); Sinvastatina 
(43;59,72%); Enoxaparina (42;58,33%); Amiodarona (29;40,27%); Sertralina 
(28;38,88%); Espironolactona (21;29,16%); e Atenolol (11;15,27%), cujas 
interações poderiam potencializar ou inibir a ação anticoagulante. Das 
interações, 14 (58,33%) eram de gravidade moderada, 10 (41,66%) maior 
e 14 (58,33%) de efeito rápido. Conclusão: A polifarmácia e o uso de 
anticoagulante oral em idosos cardiopatas é comum e, conhecer as interações 
medicamentosas, é imperativa, considerando que potencializam ou diminuem 
a ação anticoagulante, com gravidade maior ou moderada. 
Descritores: Anticoagulação, Idoso, Hospitalização, Interações de 
Medicamentos .
RESUMEN
Objetivo: Relacionar las interacciones medicamentosas de los anticoagulantes 
orales con los medicamentos utilizados por ancianos internados em um 
hospital cardiológico. Método:Estudio exploratorio, prospectivo, con 16 
ancianos en uso de anticoagulantes orales, internados en una institución 
cardiológica gubernamental de São Paulo entre noviembre y diciembre 
de 2017. Resultados:Entre 73 medicamentos prescritos y analizados en 
el Micromedex 2.0, 24 (33,3%) interactuaban con la Varfarina, único 
anticoagulante oral prescrito. Se encontró Omeprazol (70, 97,2%); Dipirona 
(68, 94,4%); Sinvastatina (43, 59,72%); Enoxaparina (42, 58,33%); Amiodarona 
(29, 40,27%); Sertralina (28, 38,88%); Espironolactona (21, 29,16%); y 
Atenolol (11, 15,27%), cuyas interacciones podrían potenciar o inhibir la 
acción anticoagulante. De las interacciones, 14 (58,33%) eran de gravedad 
moderada, 10 (41,66%) mayor y 14 (58,33%) de efecto rápido. Conclusión: 
La polifarmacia y el uso de anticoagulante oral en ancianos cardiopatas 
es común y, conocer las interacciones medicamentosas, es imperativa, 
considerando que potencian o disminuyen la acción anticoagulante, con 
gravedad mayor o moderada.
Descriptores: Anticoagulación, Ancianos, Hospitalización, Interacciones 
de medicamentos.
INTRODUCTION
The health profile of the Brazilian population has 
undergone several significant changes, such as a reduction 
in the birth rate and a reduction in mortality, a result of 
the prevalence of high fertility in the past in relation to 
the present and the improvement of living conditions 
and technological and scientific advances in the health 
area.1 This population characteristic interferes with the 
epidemiological profile and justifies the prevalence of 
chronic respiratory diseases, diabetes mellitus, neoplasms, 
renal diseases, and cardiovascular diseases, the latter being 
the main cause of mortality in Brazil, totaling 34% of all 
deaths in 2013.2,3
This morbidity profile, in addition to degenerative 
diseases, common to the elderly phase, results in 
polypharmacy (consumption of five or more drugs) 
and, consequently, facilitating the occurrence of drug 
interactions.4
Drug interaction is defined as a detectable, measurable, 
quantitative clinical event or in which there is a change in 
the effect of a drug, by the presence of another drug, food, 
beverage or some chemical agent in the environment, being 
considered interactions that occur in vitro.5,6
Drug interactions can be real, when they can be proven 
from the clinical and laboratory evaluation; or potential, 
when there is the possibility of one drug changing 
the effect of the other. Interactions depend on several 
factors, such as the clinical condition of the patient and 
the amount of the drug and mechanism of action of the 
drugs.7-9 Drug interactions can be further classified as 
follows: pharmacokinetics, pharmacodynamics, effect and 
pharmacy.8,9
In hospitalized individuals, the occurrence of drug 
interactions is greater due to polytherapy.10 And, due to 
the current morbidity profile, over the years, an important 
increase in the use of anticoagulants for the prevention and 
treatment of thromboembolic events by cardiopathies, such 
as Atrial Fibrillation (AF); in Venous Thromboembolism 
(VTE) in the form of Deep Vein Thrombosis (DVT) or 
Pulmonary Thromboembolism (PTE); and in the use of 
heart valve prostheses.11
Anticoagulants may have the following presentations: 
oral, subcutaneous and intravenous. Among Oral 
Anticoagulants (OAC), vitamin K antagonists, Warfarin 
sodium (Marevan®) or crystalline and Femprocumone 
(Marcoumar®), and the new generation of OACs that act on 
other factors of the oral coagulation cascade - Rivaroxaban, 
Dabigatran, and Apixaban. The subcutaneous or 
intravenous form is represented mainly by low molecular 
weight heparins and unfractionated heparin.12,13
Warfarin is a vitamin K antagonist absorbed in the 
gastrointestinal tract whose onset occurs after 24 hours of 
oral administration and may last from 2 to 5 days. Its action 
peak is around 72 to 96 hours and its half-life time varies 
from 20 to 60 hours. After hepatic metabolism, the drug 
is eliminated via renal (92%). The main adverse effect of 
Warfarin is bleeding, especially as it is an anticoagulant and 
requires strict dose adjustment control.14
In the hospital environment, it is the nurse professional 
responsible for the medication scheduling and management 
of the care provided, thus, it is essential for them to be 
able to avoid drug interactions, through the appropriate 
scheduling of medication. The scheduling is the moment 
in which the nurse analyzes the medical prescription and, 
adding their knowledge about medicines, defines schedules 
for their administration according to the intervals 
prescribed by the doctor and the routine of the institution’s 
scheduling.15,16
Considering that it is a competence of the registered 
nurse, in order to perform the scheduling of medications, 
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based on the technical-scientific knowledge, and to 
guarantee patient safety, a more detailed study of drug 
interactions in the pharmacological and pathophysiological 
dimensions is necessary.17,18
This study aimed to relate the drug interactions of oral 
anticoagulants to the medications used by elderly patients 
admitted to a cardiology hospital.
METHODS
It is a descriptive, prospective and documentary study 
that was carried out in a clinical-surgical hospitalization 
unit of a large hospital specialized in cardiology in São 
Paulo - SP, which has 130 beds in its infirmary.
The sample consisted of medical records of patients 
older than or equal to 60 years old, using oral anticoagulant, 
and admitted in clinical-surgical hospitalization units of 
the institution, from November to December 2016. Those 
excluded were those from the study whose records were not 
in the moment of data collection.
In order to standardize the study data, a form constructed 
by the researchers was used, consisting of identification 
data, clinical and prescribed medications, drug scheduling, 
nursing annotation on the signs and symptoms possibly 
derived from the use of these medications, and drug 
interaction with Oral Anticoagulant.
Data collection was daily, during the stipulated 
period, and for each medical record, the form was filled 
out. The analysis of drug interactions was done using the 
Micromedex 2.0 database, where all drugs were cross-
checked with the oral anticoagulant, in order to identify 
drug interactions, articulating with the nursing schedule.
Micromedex 2.0 is an information database on 
medicines, bringing recommendations based on detailed 
assessments and reports. It provides information on 
diseases, drug interactions, intravenous compatibility, 
toxicology and also allows comparing the efficacy of 
medications.19 It also classifies them as 1) contraindicated: 
Medicines are contraindicated for concomitant use; 2) 
important or high: The interaction may be life-threatening 
and/or require medical intervention to reduce or avoid 
serious adverse effects; 3) moderate: The interaction might 
result in exacerbation of the patient’s health problem 
and/or require a change in treatment.; 4) secondary: The 
interaction would result in limited clinical effects. The 
manifestations may include an increase in the frequency 
or severity of the side effects but generally, do not require 
a major change in treatment; or 5) unknown. In addition 
to this classification, the interactions can be divided as to 
their speed of onset, such as 1) fast, when the effects of the 
interaction occur within 24 hours; 2) slow, late or delayed, 
when they occur after 24 hours; and 3) unspecified, when 
there is no documentation in the literature about the 
onset of the effects of drug interaction. (Bagatini F et al. 
apud Drugdex System, Greenwood Village: Thomson 
Micromedex® Healthcare Series 20: Interactions, 2010)20,21
For the analysis, eight drugs that were prescribed to 
a greater number of patients and that interacted with 
Warfarin were selected. These, although they were the 
most prescribed ones, are not necessarily those of greater 
severity (Table 1).
The project obeyed the ethical precepts of the 
research, and was developed after approval (Certificado 
de Apresentação para Apreciação Ética (CAAE) 
[Certificate of Presentation for Ethical Appreciation] No. 
59405316.2.0000.5462) by the Research Ethics Committee 
from the institution and followed all the precepts addressed 
in the Resolution No. 466/2012 from the Comissão Nacional 
de Ética em Pesquisa (CONEP) [National Commission 
Ethics in Research].22 
RESULTS AND DISCUSSION
A total of 74 medical prescriptions of 16 patients were 
analyzed, of which 10 (62.5%) were male and 6 (37.5%) 
were female, aged 60-77 years old. The clinical profile of 
these patients is characterized by 12 (75%) hypertensive, 
7 (43.75%) dyslipidemic and 3 (18.75%) diabetic patients. 
With regards to comorbidities, 9 (56.25%) have arrhythmias; 
7 (43.75%) are of the valve; 6 (37.5%) of the myocardium; 
6 (37.5%) are former smokers; 5 (31.25%) are chronic 
renal; 4 (25%) have other comorbidities; 3 (18.75%) are 
of the pacemaker; 2 (12.5%) are of the coronary artery; 2 
(12.5%) are of the vascular; 2 (12.5%) have some neoplasm; 
1 (6.25%) are of the endovascular; and 1 (6.25%) is still 
smoking.
  The main reasons for hospitalization and current 
diagnosis were valvular heart diseases - 9 (56.25%) and 7 
(43.75%), respectively. There were 74 medical prescriptions 
with 73 drugs, with Warfarin sodium (Marevan®) being the 
only oral anticoagulant prescribed. Among medications, 
24 (33.3%) presented potential interactions with Warfarin 
(Table 2). 
Table 1. Characteristics of drug interaction
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Source: The authors 
Table 2. Drugs that interact with Warfarin
Source: The authors 
Among these, Omeprazole was present in 70 (97.2%) 
prescriptions; Dipyrone in 68 (94.4%); Simvastatin in 43 
(59.72%); to Enoxaparin in 42 (58.33%); Amiodarone in 29 
(40.27%); Sertraline in 28 (38.88%); Spironolactone in 21 
(29.16%); and Atenolol in 11 (15.27%).
Among 24 drugs that interact with Warfarin, 14 (58.33%) 
correspond to the interaction of moderate severity, while 
10 (41.66% are considered of greater severity. Regarding 
the effect, 14 (58.33%) are considered fast, and 10 (41.66%) 
are unspecified.
As for the schedule of all medications, there was 
a predominance of the following schedules: 6:00 a.m. 
(n=203), 10:00 a.m. (n=234) and 10:00 p.m. (n=315), 
which shows some standardization of the institution’s 
schedule. For instance: the institution nurse has the custom 
to schedule the medications for 2:00 p.m., 10:00 p.m. and 
6:00 a.m. when these are prescribed every 8 hours.
Warfarin was always used late afternoon, 13 times 
(17.56%) at 5:00 p.m. and 61 (82.43%) at 6:00 p.m. 
Furthermore, regarding the presence of adverse drug 
interaction events, only four (4) nursing records were 
identified. These records appeared on the nursing record 
sheet, such as back pain, haematuria, abdominal pain, and 
dizziness, all from different patients.
According to Rodrigues GHP et al. (2014)23, the most 
frequent comorbidities in the elderly and cardiopathic 
population are in agreement with the findings in this 
study when it is stated that this population is commonly 
hypertensive, diabetic, dyslipidemic, obese, chronic renal, 
coronary disease, smokers, in addition to degenerative 
diseases characteristic of the age, such as cognitive deficit. 
This current morbidity and mortality profile leads to an 
increase in the number of hospitalizations of the elderly 
and cardiopathic population. It is common, therefore, to 
notice the increase of prescriptions of drugs in hospitalized 
patients, which favors, even more, the polypharmacy and 
the possibility of a drug interaction.24
In this study, all the prescriptions analyzed contained 
more than five prescribed drugs, thus constituting 
polypharmacy.25 Among the 24 drugs that interact 
with Warfarin, the eight most prescribed drugs were 
Omeprazole, Dipyrone, Simvastatin, Enoxaparin, 
Amiodarone, Sertraline, and Atenolol.
During the collection of data, four signs or symptoms 
records presented by the patients were identified: lumbar 
pain, headache, distress sensation, and abdominal pain. 
Nevertheless, it is not possible to say with certainty if it was 
a drug interaction or not, since there are several factors 
that may have caused them. Therefore, in this study, we will 
refer to drug interactions as “potential”.
Among the 24 drugs that interact with Warfarin in 
this study, two of them (Omeprazole and Spironolactone) 
were considered of moderate severity while six (Dipyrone, 
Simvastatin, Enoxaparin, Amiodarone, Sertraline, and 
Atenolol) were considered of greater severity. Regarding 
the effect, five are delayed (Omeprazole, Simvastatin, 
Amiodarone, Sertraline, and Atenolol) and three 
unspecified (Dipyrone, Enoxaparin and Spironolactone).
The study performed by Sconce et al. (2006)26 has 
shown that concurrent use of Simvastatin and Warfarin 
results in changes in the pharmacokinetics of Warfarin, 
most likely through the inhibition of the P450 CYP3A4 
and CYP2C9 enzymes responsible for the metabolism 
of R and S-Warfarin respectively, and not by action 
on pharmacodynamics. However, Westergren (2007)27 
confirms the interaction of Warfarin with Simvastatin. 
Nonetheless, despite not being sure of the mechanism of 
this interaction, the author concludes in his study that the 
potentiation of the anticoagulant effect is caused by the 
reduction of the elimination of Warfarin.
Santos et al (2014)28 state in their study that Amiodarone 
interferes with the maintenance of the Warfarin dose; but, 
when anticoagulant therapy is already chronic, there is no 
association with adverse events. Although, caution should 
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be exercised in anticoagulant therapy concurrent with 
the use of amiodarone and that especially in the first few 
weeks, more attention is needed until the therapeutic dose 
is reached.
There are situations, such as pre and post-surgical 
procedures, in which Warfarin is discontinued, but due to 
the need to maintain anticoagulant therapy, it is decided 
the use of Enoxaparin, a type of low molecular weight and 
short-acting heparin, compared to Warfarin. Although it 
is an option of conduct with desirable effect, there can be 
serious consequences, such as an increased risk of bleeding, 
because it is another anticoagulant.29
There are few studies on the interaction between 
Warfarin and Spironolactone, but O’Reilly (1980)30 suggests 
that the mechanism of this interaction is summarized 
by the diuretic effect of spironolactone whose product 
concentrates on coagulation factors, thereby decreasing the 
anticoagulant effect of Warfarin.
In the study made by Apseloff (1997)31, it was found 
that the result of the interaction between Warfarin and 
Sertraline - the potentiation of the anticoagulant effect, 
is clinically insignificant. Nevertheless, regular care and 
monitoring of the International Normalized Ratio (INR) 
levels should be maintained. The same is true for the 
interaction between Warfarin and Omeprazole, according 
to Sutfin (1989)32. No studies were found to elucidate the 
interaction between Warfarin and Atenolol, nor between 
Warfarin and Dipyrone. Groia (2015)33 that only affirms 
the possible first interaction whose result is the risk of 
increasing INR.
In this study, the combination of Paracetamol and 
Codeine was prescribed only twice and for two patients, 
but it was not known whether the prescriber and those 
who took and administered had knowledge about the 
potential drug interaction or was actually a risk-benefit 
assessment. Therefore, Paracetamol is a Nonsteroidal 
Anti-Inflammatory Drug (NSAID) with an analgesic and 
antipyretic effect, widely used domestically.36 It is known 
from clinical practice that its concomitant use of Warfarin 
can cause considerable damage, such as bleeding. This 
interaction is considered of moderate severity and slow 
effect.19-36 Mahé I (2005)37 confirms that Paracetamol 
potentiates the anticoagulant effect of Warfarin, although 
this mechanism is still unclear.
At the institution where the study was conducted, 
Warfarin is generally scheduled in the late afternoon. And, 
in the present study, the only hours of scheduling were at 
5:00 p.m. and 6:00 p.m. There is no documented scientific 
justification for this routine in the literature, but since 
routinely routine exams are collected in the morning until 
the time of the administration of Warfarin, the INR is likely 
to be ready. Hence, if necessary, it is possible to change the 
OAC dose at the time of its administration.34,35
CONCLUSIONS
Warfarin is an oral vitamin K antagonist with action 
duration of about two to five days and usually of continuous 
use. Therefore, prolonged action. Considering the high 
interaction power with several drugs, which may result in 
potentiation or inhibition of the anticoagulant action, it 
is important that the individual using oral anticoagulant 
periodically controls the INR, nor as directed for potential 
drug interactions, which may result in new treatments, 
hospitalizations and, consequently, the burden of health 
expenses, which can be avoided.
Nonetheless, it cannot be affirmed that nursing care 
is essential to avoid drug interactions in individuals who 
use Warfarin precisely because of the continuous action 
of it. However, regardless of the timing of Warfarin or any 
medications that interact with it, it is important to know 
the effects that the drug interaction can cause, in order 
to allow corrective action or immediate control, much 
more than to pay attention to the release itself, which 
may not be avoidable. Furthermore, it is vital that both 
physicians and nurses can identify the drugs that should 
not be concomitantly administered. The first, considering 
the prescription; and the second, with regards to the drug 
scheduling.
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